Eli Lilly

Revenue jumped 56 percent in the first quarter of 2026 to 19.8 billion dollars, and full-year 2025 sales hit 65.2 billion dollars, up 45 percent. The weight-loss and diabetes franchise grew so fast that net income nearly tripled to 7.4 billion dollars in a single quarter. Very few large companies grow anywhere near this pace.

Lilly keeps about 35 cents of profit on every dollar of sales, an exceptional margin. That fueled more than 16.8 billion dollars of operating cash flow in 2025, money the company is now pouring into new factories and dozens of deals to build its next wave of medicines. Strength like this lets it invest while rivals struggle.

Two drugs, Mounjaro and Zepbound, make up roughly 65 percent of revenue. If demand for weight-loss shots cools or a competitor leaps ahead, the whole story slows down fast. One study found that nearly half of diabetes patients quit these drugs within a year, so staying power is a real question.

The stock trades near all-time highs at about 30 times next year's expected earnings, far above the typical drugmaker. At that price there is little room for error, so any stumble in sales or a setback for newer pills like Foundayo could trigger a sharp drop. You are paying up for the growth.